Mankind Pharma Limited Stock Price Today (NSE: MANKIND)
Fundamental Score
Mankind Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Mankind Pharma Limited share price today is ₹2365.00, down 0.63% on NSE/BSE as of 25 August 2026. Mankind Pharma Limited (MANKIND) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.05L (Cr). The 52-week high for MANKIND share price is ₹2674.00 and the 52-week low is ₹1909.70. At a P/E ratio of 51.28x, MANKIND is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 12.49% and a debt-to-equity ratio of 0.39.
Mankind Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Mankind Pharma Limited share price chart: -7.24% return over the past month. 52-week high ₹2674.00, 52-week low ₹1909.70.
Mankind Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2374.40 | ₹2374.40 | ₹2337.60 | ₹2365.00 | 4.16L (Cr) | |
| ₹2370.00 | ₹2395.00 | ₹2363.30 | ₹2380.00 | 3.66L (Cr) | |
| ₹2412.50 | ₹2458.00 | ₹2412.50 | ₹2425.20 | 4.65L (Cr) | |
| ₹2430.50 | ₹2430.50 | ₹2392.00 | ₹2404.40 | 1.29L (Cr) | |
| ₹2418.00 | ₹2433.10 | ₹2381.30 | ₹2433.10 | 7.54L (Cr) | |
| ₹2429.00 | ₹2439.60 | ₹2405.50 | ₹2425.00 | 2.30L (Cr) | |
| ₹2450.00 | ₹2485.00 | ₹2428.50 | ₹2438.00 | 2.31L (Cr) | |
| ₹2430.00 | ₹2456.00 | ₹2415.60 | ₹2456.00 | 1.67L (Cr) | |
| ₹2450.00 | ₹2463.80 | ₹2420.30 | ₹2420.30 | 2.42L (Cr) | |
| ₹2461.00 | ₹2461.90 | ₹2435.00 | ₹2435.60 | 1.58L (Cr) |
Mankind Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2458.00 | ₹2497.90 | ₹2337.60 | ₹2365.00 | -3.78% | |
| ₹2555.90 | ₹2642.00 | ₹2422.00 | ₹2469.60 | -3.38% | |
| ₹2399.80 | ₹2604.00 | ₹2275.60 | ₹2545.60 | +6.08% | |
| ₹2249.20 | ₹2638.60 | ₹2239.60 | ₹2375.60 | +5.62% | |
| ₹2016.00 | ₹2322.20 | ₹1928.00 | ₹2246.70 | +11.44% | |
| ₹2161.00 | ₹2256.80 | ₹1909.70 | ₹2005.80 | -7.18% | |
| ₹2100.00 | ₹2284.90 | ₹2012.30 | ₹2247.60 | +7.03% | |
| ₹2202.00 | ₹2320.90 | ₹2059.40 | ₹2124.00 | -3.54% | |
| ₹2260.00 | ₹2260.00 | ₹2090.00 | ₹2196.50 | -2.81% | |
| ₹2383.30 | ₹2408.60 | ₹2198.50 | ₹2251.00 | -5.55% | |
| ₹2420.00 | ₹2511.90 | ₹2368.00 | ₹2384.00 | -1.49% | |
| ₹2473.50 | ₹2674.00 | ₹2425.00 | ₹2435.70 | -1.53% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Mankind Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Mankind Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MANKIND across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (25.82%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (30.98%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Cash Generation (₹5696.67 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (72.67%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 51.28x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (6.44x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Mankind Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Mankind Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Mankind Pharma LimitedMankind Pharma ...Selected✓ MANKIND • 543904 | 61.5/100 | ₹2365.00₹2365 | ₹105053.91₹105053.91 | 51.28Average 51.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | — — | — — | 0.04% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1875.10₹1875 | ₹468821.49₹468821.49 | 38.76Average 38.8 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹8588.00₹8588 | ₹193163.97₹193163.97 | 66.04Average 66.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4971.00₹4971 | ₹169902.02₹169902.02 | 77.90Average 77.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1431.10₹1431 | ₹116131.81₹116131.81 | 34.45Average 34.5 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1115.60₹1116 | ₹115375.77₹115375.77 | 25.57Average 25.6 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2232.00₹2232 | ₹113976.53₹113976.53 | 20.62Average 20.6 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1178.80₹1179 | ₹102660.46₹102660.46 | 31.86Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1645.00₹1645 | ₹90035.87₹90035.87 | 24.25Average 24.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1814.00₹1814 | ₹84016.75₹84016.75 | 76.84Average 76.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | — — | 7.19%Good 7.19% Good | 0.13% |
Biocon LimitedBiocon Limited... BIOCON • 532523 | 30.2/100 | ₹417.50₹418 | ₹70826.50₹70826.50 | 143.00Average 143.0 Average | 1.39%Poor 1.39% Poor | 3.06%Poor 3.06% Poor | 0.44Excellent 0.4 Excellent | -12.23%Poor -12.23% Poor | 18.96%Excellent 18.96% Excellent | 0.12% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price468821.49 Cr
- Divi's Laboratories Limited share price193163.97 Cr
- Torrent Pharmaceuticals Limited share price169902.02 Cr
- Cipla Limited share price116131.81 Cr
- Zydus Lifesciences Limited share price115375.77 Cr
Mankind Pharma Limited PE Ratio History
Historical price-to-earnings ratio for MANKIND — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹49.20 | ₹2196.50 | 44.6x |
| FY 2024 | ₹47.68 | ₹2880.40 | 60.4x |
| FY 2023 | ₹32.00 | ₹1982.50 | 62x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Mankind Pharma Limited Quarterly Performance
Latest quarterly metrics for MANKIND — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
12.89%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
30.98%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Mankind Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MANKIND — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Mankind Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Mankind Pharma Limited (MANKIND) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Mankind Pharma Limited
About MANKIND (Mankind Pharma Limited)
Mankind Pharma Ltd is a prominent pharmaceutical company committed to enhancing healthcare accessibility across India and beyond. With a robust foundation built on innovation and a...ffordability, the company formulates, produces, and commercializes a diverse portfolio of pharmaceutical products and consumer healthcare solutions. Mankind Pharma distinguishes itself by addressing critical therapeutic needs in both acute and chronic disease management. Its pharmaceutical offerings encompass a wide range of therapeutic areas, including treatments for infections, cardiovascular conditions, gastrointestinal disorders, gynecological issues, diabetes, dermatological ailments, pain management, neurological conditions, and respiratory illnesses. Through its dedication to providing high-quality medicines at affordable prices, Mankind Pharma has established a strong presence in the Indian pharmaceutical market. Beyond its pharmaceutical endeavors, Mankind Pharma also caters to consumer healthcare needs with a range of well-known products. This segment includes well-known items aimed at promoting overall wellness and reproductive health. These consumer healthcare products complement the company's pharmaceutical offerings, reinforcing its commitment to comprehensive healthcare solutions. The company aims to empower individuals to take proactive control of their health, contributing to improved well-being and a better quality of life. Through these products, Mankind Pharma reinforces its mission of providing reliable and accessible healthcare options for all, further solidifying its position as a trusted healthcare provider. Mankind Pharma remains dedicated to expanding its research and development capabilities to introduce innovative and effective healthcare solutions. By focusing on continuous improvement and strategic collaborations, the company is well-positioned to meet the evolving needs of patients and healthcare professionals. With a strong commitment to quality, affordability, and accessibility, Mankind Pharma continues to play a vital role in the pharmaceutical landscape, both domestically and internationally. Its dedication to providing accessible and effective healthcare options has positioned Mankind Pharma as a significant contributor to the well-being of individuals and communities across India and beyond.
Company Details
Key Leadership
MANKIND Share Price: Frequently Asked Questions
What is the current share price of Mankind Pharma Limited?
Mankind Pharma Limited (MANKIND) trades at ₹2365.00 on NSE and BSE. Market cap ₹1.05L (Cr). Educational data only.
What is the P/E ratio of Mankind Pharma Limited?
Mankind Pharma Limited has a P/E of 51.28x vs industry average 34.89x.
What is the Bull Run score for Mankind Pharma Limited?
Mankind Pharma Limited has a Bull Run score of 61.5/100 based on 25+ financial parameters.
Does Mankind Pharma Limited pay dividends?
Mankind Pharma Limited has a dividend yield of 0.04%. Past dividends don't guarantee future payments.
What is the ROE of Mankind Pharma Limited?
Mankind Pharma Limited has ROE of 12.49%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Mankind Pharma Limited?
Mankind Pharma Limited has debt-to-equity of 0.39.
Is Mankind Pharma Limited a good investment?
Bull Run gives Mankind Pharma Limited a score of 61.5/100. This is not investment advice — consult a SEBI-registered advisor.